For an uninterrupted learning experience, please use Google Chrome, Safari or Firefox as your browser. If you use Internet Explorer, you may not be able to view or access parts of this course.*

Note: This course will expire 90 days from the date of registration. Please complete the course within that time frame or you may have to begin the program again. If you have questions, email MAT@apna.org   DO NOT REREGISTER for the course, contact MAT@apna.org

Course Description: 

This course is jointly provided by Providers Clinical Support System (PCSS) and American Psychiatric Nurses Association (APNA). The course consists of 16 individual sessions which are part of the required 24 hours of content for nurses who wish to offer medication assisted treatments for substance use disorders including buprenorphine. Each module includes a webinar, post-test, and evaluation. There is a final course evaluation, honor statement and certification of course completion. IF you have questions, email MAT@apna.org

Target Audience: APRN

Learning Outcomes:
Upon completion of the course, learners will be able to:

1. Describe foundational prescriptive principles related to medications for person with diagnoses of substance use disorders, including buprenorphine, in order to decrease opioid use and opioid related deaths in the United States. 
2. Discuss issues related to assessment protocols when prescribing medication assisted treatments for persons with diagnoses of substance use disorders. 
3. Articulate the roles, responsibilities and limitations of a provider, as described in the current regulations, related to medication assisted treatments for persons with substance use disorders/opioid use disorders.

Nursing Continuing Professional Development:
16.0 pharmacology contact hours.*In order to receive contact hours for the program, participants must: View the program in its entirety, earn a passing score of at least 80% on the post-test for each module, complete evaluations of each module and complete the final course evaluation during the allotted 90-day access period. Participants will have 5 opportunities to correctly answer the questions on the post-tests. If you are unable to successfully pass a module post-test, contact MAT@APNA.org. Following completion of the modules, post-tests and evaluations, the certificate will be generated online, available for immediate printing. Credit will not be earned unless all components of the program are completed. Partial credit will not be earned.

Pricing: Free

Keywords: Addictions, MAT Training, Substance Use Disorders

Register:  

• The course is free of charge and can be accessed by clicking the Register button above. You will be prompted to login with your APNA account information. If you do not have an APNA account, select the button, "create an account" and complete the listed information to create a free non-member profile. 
• After completing all 24 hours of training, return to the PCSS website to continue the waiver process. DEA waiver instructions are provided at the PCSS website.
• Click here for the "Steps to Obtain Your MAT Waiver" process map.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation of this nursing continuing professional development educational activity does not imply endorsement by APNA or ANCC of any commercial products discussed in the context of this activity. 

Funding Statement:  
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Disclosures:

• The APNA nurse planner and members of the APNA planning committee have no financial relationships or conflict of interest to disclose. A faculty statement of disclosure is included within each module. This educational activity may contain discussion of off-label usage of drugs that are not indicated by the FDA. The APNA and the American Academy of Addiction Psychiatry (AAAP) do not recommend usage of any agent outside the FDA approved/labeled indications.

Release Date: February 24, 2020
The contact hours for this session expire: February 28, 2023

*Internet Explorer is an outdated browser and therefore when using it, APNA eLearning Center courses often will not load or play properly. Because Internet Explorer is still the default browser on many devices, this is the number one issue that impacts learners’ ability to access their courses. For an uninterrupted learning experience, please download and use Google Chrome, Mozilla Firefox, Microsoft Edge, Safari, etc. If you continue to experience issues, you may need to update your browser.